DoW Kidney Cancer, Concept Award

The Kidney Cancer Research Program Concept Award is administered by the Defense Health Agency through the Congressionally Directed Medical Research Programs. This funding opportunity is designed to stimulate highly innovative and exploratory research in the field of kidney cancer. The program is rooted in a broader federal effort to advance medical research that benefits service members, veterans, their families, and the general public. Since its inception, the Kidney Cancer Research Program has received substantial congressional appropriations to support impactful scientific discovery, with a mission centered on conquering kidney cancer through collaboration and innovation. The primary purpose of the Concept Award is to support novel, untested, and potentially groundbreaking ideas that challenge existing paradigms in kidney cancer research. Unlike traditional research grants, this mechanism explicitly prohibits the inclusion of preliminary data, emphasizing high-risk, high-reward proposals that may open entirely new avenues of investigation. Applicants must demonstrate how their proposed concept introduces a new line of inquiry or significantly enhances current understanding of kidney cancer biology, diagnosis, treatment, or patient care. Funding is structured with a total program allocation of approximately $840,000 to support around seven awards. Each award has a maximum total cost cap of $120,000 and a performance period limited to one year. Funds may be used for research-related expenses including personnel, supplies, and limited travel for collaboration or dissemination of findings. However, clinical trials are not permitted, and certain restrictions apply, such as limitations on travel funding and prohibitions on specific types of animal research. There is no requirement for cost sharing or matching funds. Eligibility for this opportunity is broad and inclusive, allowing applications from both domestic and international organizations across public, private, nonprofit, and for-profit sectors. Principal Investigators must be at least at the postdoctoral level and may submit only one application under this mechanism. Awards are made to organizations rather than individuals, and all applicants must maintain active registrations in federal systems such as SAM.gov, eBRAP, and Grants.gov prior to submission. The application process follows a two-step submission model. First, applicants must submit a pre-application in the form of a Letter of Intent through the eBRAP system. This is followed by a full application submission through either Grants.gov or eBRAP, depending on the applicant type. The full application includes multiple components such as a project narrative, statement of work, impact statement, innovation statement, and supporting documentation. Strict anonymization rules apply during review, requiring removal of any identifying information from key narrative sections. Applications undergo a rigorous two-tier review process consisting of peer review and programmatic review. Peer review evaluates innovation, impact, and research strategy, while programmatic review assesses alignment with program priorities and overall portfolio balance. The review process is conducted in a blinded manner to ensure impartiality. Awards are expected to be announced following review cycles, with funding decisions contingent on merit, relevance, and availability of federal funds. Key deadlines for this funding opportunity include a pre-application submission due in late July and a full application due in mid-August. The review process spans several months, with peer review occurring in the fall and programmatic review in early winter. Awards are anticipated to be finalized by the following year, and funded projects must comply with reporting requirements and federal research regulations throughout the award period.

Focus on highly innovative concepts without preliminary data; ensure strict anonymization; align proposal with kidney cancer focus areas and demonstrate high impact potential